Tinja Tablet 150 mg (Nizatidine)

Adult dose

1. Treatment of active gastric or duodenal ulcers For adults, administer nizatidine 300mg once daily at bedtime, or 150mg twice daily, in the morning and evening, orally. Most ulcers heal within 4 weeks, but treatment may be continued for up to 8 weeks if necessary. 2. Prevention of duodenal ulcer recurrence For adults, after healing of a duodenal ulcer, administer 150mg orally once daily at bedtime. Treatment may be continued for up to 1 year; results with longer-term treatment are not known. 3. Gastroesophageal reflux disease For adults, administer 150mg orally twice daily, in the morning and evening. Treatment may be continued for up to 12 weeks. 4. Improvement of gastric mucosal lesions For adults, administer 150mg orally twice daily, in the morning and evening, for 2 weeks. 5. Dose adjustment for patients with severe renal impairment The dose for patients with renal impairment should be reduced and adjusted as follows. Creatinine clearance 20~50 ml/min: Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: 150mg daily Creatinine clearance < 20 ml/min: Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: 150mg every other day Maintenance therapy Creatinine clearance 20~50 ml/min: 150mg every other day Creatinine clearance < 20 ml/min: 150mg every 3 days

This drug should not be used in patients with hypersensitivity to H2-receptor antagonists. Extra caution is needed if there has been an allergic reaction to a similar drug. Patients with a history of hypersensitivity to medications should be careful when taking this drug. Patients with liver dysfunction should also be careful when using this drug. Patients with reduced kidney function may have an increased blood concentration of this drug, necessitating a lower dose or extended dosing intervals. If any allergic symptoms such as skin rash, itching, or difficulty breathing occur while using this drug, it should be discontinued immediately. Blood abnormalities such as anemia, leukopenia, and thrombocytopenia may occur, and if any abnormal symptoms are observed, the medication should be stopped. Gastrointestinal issues such as constipation, diarrhea, and nausea may occur, so symptoms should be monitored. Liver function tests may show increased levels, or symptoms such as hepatitis and jaundice may appear, so liver status should be checked periodically. Rarely, neurological issues such as confusion, headache, drowsiness, and dizziness may occur. Heart rate may become abnormally fast, so cardiac condition should be monitored closely. Rarely, women may experience breast enlargement, and men have reported sexual dysfunction. Skin reactions such as rash, sweating, and hives may occur, so symptoms should be watched carefully. This drug is primarily excreted through the kidneys, so elderly patients or those with impaired kidney function should adjust dosage based on kidney function tests. Women who are pregnant or breastfeeding should consult their doctor before use due to potential effects on the fetus or newborn. Safety in pediatric patients has not been established, so caution should be exercised in children. This drug may mask symptoms of gastric cancer, so it should be confirmed that the patient does not have gastric cancer before use. In cases of overdose, symptoms such as vomiting, diarrhea, and pupillary constriction may appear; if suspected, seek medical attention immediately. This drug has a low potential for interactions with other medications, but caution is advised when used with high-dose aspirin.

• Rash
• itching
• bronchial asthma
• laryngeal edema
• anaphylactic symptoms
• anemia
• leukopenia
• neutrophilia
• thrombocytopenic purpura
• constipation

This drug should be stored in a tightly sealed container to avoid exposure to air or moisture, and it is safe to store at room temperature between 15 and 30 degrees. Therefore, it is important to avoid direct sunlight and not to place it in excessively hot or cold places.

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle